FLINGO – 200
Tablets & FLINGO suspension
COMPOSITION
FLINGO-200
Tablets Each film-coated tablet
contains Ofloxacin 200 mg
FLINGO
SUSPENSION - UPCOMING
Each 5ml contains
Ofloxacin
50 mg
INDICATIONS
To reduce
the development of drug-resistant bacteria and maintain the
effectiveness of ofloxacin tablets and other antibacterial drugs,
ofloxacin tablets should be used only to treat or prevent
infections that are proven or strongly suspected to be caused by
susceptible bacteria. When culture and susceptibility information
are available, they should be considered in selecting or modifying
antibacterial therapy.In the absence of such data, local
epidemiology and susceptibility patterns may contribute to the
empiric selection of therapy.
Ofloxacin
tablets are indicated for the treatment of adults with mild to
moderate infections (unless otherwise indicated) caused by
susceptible strains of the designated microorganisms in the
infections listed below.
Acute bacterial
exacerbations of chronic bronchitis due
to Haemophilus influenzae orStreptococcus
pneumoniae.
Community-acquired
Pneumonia due to Haemophilus influenzae or
Streptococcus pneumoniae.
Uncomplicated
skin and skin structure infections due
to methicillin-susceptible Staphylococcus
aureus, Streptococcus pyogenes,
or Proteus mirabilis.
Acute,
uncomplicated urethral and cervical gonorrhea due
to Neisseria gonorrhoeae.Nongonococcal
urethritis and cervicitis due
to Chlamydia trachomatis.
Mixed Infections
of the urethra and cervix due to Chlamydia
trachomatis and Neisseria
gonorrhoeae.
Acute pelvic
inflammatory disease (including severe
infection) due to Chlamydia
trachomatisand/or Neisseria
gonorrhoeae.
NOTE: If
anaerobic microorganisms are suspected of contributing to the
infection, appropriate therapy for anaerobic pathogens should be
administered.
Uncomplicated
cystitis due to Citrobacter
diversus, Enterobacter
aerogenes, Escherichia coli, Klebsiella
pneumoniae, Proteus mirabilis,
or Pseudomonas aeruginosa.
Complicated
urinary tract infections due to Escherichia
coli, Klebsiella pneumoniae, Proteus
mirabilis, Citrobacter diversus*,
or Pseudomonas aeruginosa*.
Prostatitis due
to Escherichia coli.
* =
Although treatment of infections due to this organism in this organ
system demonstrated a clinically significant outcome, efficacy was
studied in fewer than 10 patients.
Appropriate culture and
susceptibility tests should be performed before treatment in order
to isolate and identify organisms causing the infection and to
determine their susceptibility to ofloxacin. Therapy with ofloxacin
may be initiated before results of these tests are known; once
results become available, appropriate therapy should be
continued.
As with
other drugs in this class, some strains of Pseudomonas
aeruginosa may develop resistance fairly rapidly during
treatment with ofloxacin. Culture and susceptibility testing
performed periodically during therapy will provide information not
only on the therapeutic effect of the antimicrobial agent but also
on the possible emergence of bacterial resistance.
DOSAGE AND
ADMINISTRATION
Adult
Dosage
The usual
dose of ofloxacin tablets is 200 mg to 400 mg orally every 12 h as
described in the following dosing chart. These recommendations
apply to patients with normal renal function (i.e., creatinine
clearance > 50 mL/min).
Infection†
|
Unit
Dose
|
Frequency
|
Duration
|
Daily
Dose
|
Acute
Bacterial Exacerbation of Chronic Bronchitis
|
400
mg
|
q12h
|
10
days
|
800
mg
|
Comm.
Acquired Pneumonia
|
400
mg
|
q12h
|
10
days
|
800
mg
|
Uncomplicated Skin and
Skin Structure Infections
|
400
mg
|
q12h
|
10
days
|
800
mg
|
Acute,
Uncomplicated Urethral and Cervical Gonorrhea
|
400
mg
|
single
dose
|
1
days
|
400
mg
|
Nongonococcal
Cervicitis/Urethritis due to C. trachomatis
|
300
mg
|
q12h
|
7
days
|
600
mg
|
Mixed
Infection of the urethra and cervix due to C. trachomatis and N.
gonorrhoeae
|
300
mg
|
q12h
|
7
days
|
600
mg
|
Acute
Pelvic Inflammatory Disease
|
400
mg
|
q12h
|
10-14
days
|
800
mg
|
Uncomplicated Cystitis
due to E. coli or K. pneumoniae
|
200
mg
|
q12h
|
3
days
|
400
mg
|
Uncomplicated Cystitis
due to other approved pathogens
|
200
mg
|
q12h
|
7
days
|
400
mg
|
Complicated
UTI's
|
200
mg
|
q12h
|
10
days
|
400
mg
|
Prostatitis due to
E.Coli
|
300
mg
|
q12h
|
6
weeks
|
600
mg
|
† DUE TO
THE DESIGNATED PATHOGENS
Antacids
containing calcium, magnesium, or aluminum; sucralfate; divalent or
trivalent cations such as iron; or multivitamins containing zinc;
or didanosine should not be taken.
Patients with
Impaired Renal Function
Dosage
should be adjusted for patients with a creatinine clearance < 50
mL/min. After a normal initial dose, dosage should be adjusted as
follows:
Creatinine
Clearance
|
Maintenance
Dose
|
Frequency
|
20-50
mL/min
|
the usual
recommended unit dose
|
q24h
|
< 20
mL/min
|
½ the
usual recommended unit dose
|
q24h
|
When only
the serum creatinine is known, the following formula may be used to
estimate creatinine clearance.
Men:
Creatinine clearance (mL/min) =
|
Weight (kg) x (140 – age)
72 x serum
creatinine (mg/dL)
|
Women:
0.85 x the value calculated for men.
The serum
creatinine should represent a steady-state of renal
function.
Patients with
Cirrhosis
The
excretion of ofloxacin may be reduced in patients with severe liver
function disorders (e.g., cirrhosis with or without ascites). A
maximum dose of 400 mg of ofloxacin per day should therefore not be
exceeded.
CONTRAINDICATIONS
Ofloxacin
tablets is contraindicated in persons with a history of
hypersensitivity associated with the use of ofloxacin or any member
of the quinolone group of antimicrobial agents.
PACKAGING
INFORMATION
FLINGO-200
Tablets..............
ALU-ALU Pack of 10 Tablets
FLINGO-
SUSPENSION ...............60ML pet bottle -
Upcoming
|